Quark Pharmaceuticals, Inc. Company Profile

03:38 EST 18th November 2017 | BioPortfolio

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference is a biological process in which RNA molecules regulate expression of targeted genes. Quark’s fully integrated drug discovery and development platform spans the process from therapeutic target identification to drug development. Two products, QPI-1002 for delayed graft function (DGF) following kidney transplantation and QPI -1007 for non-arteritic ischemic optic neuropathy (NAION), have been granted orphan designation and are in global Phase 2/3 pivotal clinical studies. Quark’s broad pipeline of clinical and preclinical product candidates is generated from the company’s internally-developed siRNAi platform technology and focuses on extrahepatic indications. In July this year, Quark has successfully completed a randomized double-blinded Phase 2 trial exploring efficacy of QPI-1002 in prevention of acute kidney injury (AKI) following cardiac surgery that met the primary and multiple secondary endpoints. Novartis has an option to license this product. Another Quark’s siRNA pipeline drug, PF-655 is licensed to Pfizer. Quark is headquartered in Fremont, California and operates research facilities in Ness-Ziona, Israel. For additional information please visit:

News Articles [480 Associated News Articles listed on BioPortfolio]

Quark Pharmaceuticals Reports Positive Phase 2 Results to Evaluate the Efficacy and Safety of QPI-1002

NewsThe study included 341 subjects of age 45 or greater undergoing cardiac surgery and at risk for AKI.

Quark-level analogue of nuclear fusion with doubly heavy baryons

The essence of nuclear fusion is that energy can be released by the rearrangement of nucleons between the initial- and final-state nuclei. The recent discovery of the first doubly charmed baryon , whi...

Quark Pharmaceuticals Inc. Reports Positive Results From A Phase II Study To Evaluate The Efficacy And Safety Of QPI-1002 For The Prevention Of Acute Kidney Injury (AKI) In Subjects At High Risk Of AKI Following Cardiac Surgery

  Life Sciences Jobs   ...

Silence Therapeutics notes positive Phase II study results by licensee Quark Pharmaceutical for prevention of Acute Kidney Injury

Silence Therapeutics (LON:SLN) noted today that its licensee Quark Pharmaceutical Inc has reported positive results from a Phase 2 Study to evaluate the efficacy and safety of its QPI-1002 therapy for...

Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for ...

-- First systemic siRNA to reach the clinic, QPI-1002 reduced incidence, relative risk, severity and duration of Acute Kidney Injury (AKI) compared to placebo -- Read more...

Global and Asia RNAi for Therapeutic Market Status and Future Forecast 20132023 [Report Updated: 05102017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Quark siRNA meets Phase II kidney injury endpoint

Quark's QPI-1002 meets Phase II kidney injury endpoint

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]


PubMed Articles [137 Associated PubMed Articles listed on BioPortfolio]

Detection of magnetized quark-nuggets, a candidate for dark matter.

Quark nuggets are theoretical objects composed of approximately equal numbers of up, down, and strange quarks and are also called strangelets and nuclearites. They have been proposed as a candidate fo...

Proper time regularization and the QCD chiral phase transition.

We study the QCD chiral phase transition at finite temperature and finite quark chemical potential within the two flavor Nambu-Jona-Lasinio (NJL) model, where a generalization of the proper-time regul...

Constraining Light-Quark Yukawa Couplings from Higgs Distributions.

We propose a novel strategy to constrain the bottom and charm Yukawa couplings by exploiting Large Hadron Collider (LHC) measurements of transverse momentum distributions in Higgs production. Our meth...

Five-Loop Running of the QCD Coupling Constant.

We analytically compute the five-loop term in the beta function which governs the running of α_{s}-the quark-gluon coupling constant in QCD. The new term leads to a reduction of the theory uncertaint...

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Clinical Trials [209 Associated Clinical Trials listed on BioPortfolio]

The ICALIC International Multicentric Study

This study will evaluate the ease of use of the new calorimeter (Quark RMR 2.0 (COSMED, Italy)) in intensive care unit (ICU) patients compared to currently used calorimeters (i.e. Quark RM...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Companies [1287 Associated Companies listed on BioPortfolio]

Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference ...

Quark Biotech, Inc.

Quark Biotech, Inc., is a biopharmaceutical company headquartered in the U.S., focused on the development of drugs based in its proprietary target genes.Quark has developed a broad technology portfoli...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Quark Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Quark Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Quark Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Quark Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Quark Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Quark Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record